We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

81 hedge funds and large institutions have $153M invested in Ovid Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,700% more call options, than puts

Call options by funds: $28K | Put options by funds: $1K

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

22% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 23

5% more funds holding

Funds holding: 77 → 81 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.41% less ownership

Funds ownership: 73.28% → 70.87% (-2.4%)

8% less capital invested

Capital invested by funds: $167M → $153M (-$13.9M)

Holders
81
Holders Change
+4
Holders Change %
+5.19%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
28
Reduced
23
Closed
8
Calls
$28K
Puts
$1K
Net Calls
+$27K
Net Calls Change
+$19K

Top Buyers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
+$3.29M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$746K
3
Millennium Management
Millennium Management
New York
+$488K
4
Citadel Advisors
Citadel Advisors
Florida
+$456K
5
UOC
UBS O'Connor
Illinois
+$385K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$10M
2
Morgan Stanley
Morgan Stanley
New York
-$562K
3
BlackRock
BlackRock
New York
-$417K
4
VPC
Vestal Point Capital
New York
-$275K
5
BCM
Bridgeway Capital Management
Texas
-$273K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$449K +$456K +136,137 +1,215%
Millennium Management
27
Millennium Management
New York
$445K +$488K +145,965 New
EF
28
Empowered Funds
Pennsylvania
$391K +$32.2K +9,625 +8%
N
29
Nuveen
North Carolina
$363K +$16.8K +5,028 +4%
Assenagon Asset Management
30
Assenagon Asset Management
Luxembourg
$349K +$120K +35,786 +46%
Morgan Stanley
31
Morgan Stanley
New York
$305K -$562K -167,927 -63%
Fidelity Investments
32
Fidelity Investments
Massachusetts
$263K +$3.29K +982 +1%
Connor, Clark & Lunn Investment Management (CC&L)
33
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$257K +$10.2K +3,058 +4%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$252K +$9.76K +2,918 +4%
UBS Group
35
UBS Group
Switzerland
$224K +$4.98K +1,489 +2%
TC
36
Tejara Capital
United Kingdom
$223K – – –
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$217K -$23.4K -7,003 -9%
Squarepoint
38
Squarepoint
New York
$208K +$191K +56,962 +501%
Jacobs Levy Equity Management
39
Jacobs Levy Equity Management
New Jersey
$190K – – –
Goldman Sachs
40
Goldman Sachs
New York
$180K -$9.41K -2,811 -5%
Jane Street
41
Jane Street
New York
$163K +$8.96K +2,679 +5%
Bank of Nova Scotia
42
Bank of Nova Scotia
Ontario, Canada
$135K – – –
Barclays
43
Barclays
United Kingdom
$129K -$134K -39,924 -49%
Two Sigma Investments
44
Two Sigma Investments
New York
$124K +$136K +40,669 New
SG Americas Securities
45
SG Americas Securities
New York
$110K -$12.9K -3,854 -10%
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$98.1K +$46K +13,756 +75%
Invesco
47
Invesco
Georgia
$90.1K -$1.11K -331 -1%
AIG
48
American International Group
New York
$89.6K -$847 -253 -0.9%
First Manhattan
49
First Manhattan
New York
$79.3K – – –
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$79.2K +$3.78K +1,130 +5%
1
2
3 4

OVID Hedge Fund Activity: Q1 2024 in Review

81 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2024, worth a combined $153M — down 8.4% from $167M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new OVID positions and 8 closed out — a net gain of 4 holders — while 28 added to existing stakes and 23 trimmed.

The largest buyer was Prosight Management, opening a new position worth an estimated $3.29M. The largest seller was BVF Inc, cutting an estimated $10M.

  • 81 institutional investors held Ovid Therapeutics (OVID) as of Q1 2024, up from 77 in Q4 2023.
  • Funds reported $153M of Ovid Therapeutics stock for Q1 2024, down 8.4% quarter-over-quarter.
  • 12 funds opened new Ovid Therapeutics positions in Q1 2024 and 8 closed out, a net change of +4 holders.
  • The largest Ovid Therapeutics buyer in Q1 2024 was Prosight Management, an estimated $3.29M added.
  • The largest Ovid Therapeutics seller in Q1 2024 was BVF Inc, an estimated $10M sold.

Based on aggregated 13F filings for Q1 2024.